This page uses cookies
Due to the settings of your browser and in order to facilitate the functioning of the umcs.pl webpage, the cookies have been installed. By continuing to use this webpage, you accept their usage. You can change this in the settings of you browser.
We are pleased to announce that UMCS has received a new patent entitled: Protein-sugar fraction of Dendrobaenaveneta calamitous fluid for use in non-specific immunotherapy.
The inventors are:
employees of the Institute of Biological Sciences.
The decision to grant the exclusive right to the invention was issued by the Patent Office of the Republic of Poland on 25th May 2021.
The subject of the invention is a high-molecular-weight protein-sugar fraction isolated from the celomic fluid of Dendrobaena Veneta, which activates (stimulates) human macrophages in vitro and causes the secretion of pro-inflammatory cytokines (messenger proteins) by these cells: interleukin 6 (IL-6) and interleukin 1b (IL- 1b).
The obtained preparation can be used as a pharmaceutical composition that increases resistance to infections (e.g. an immunostimulating drug) or locally enhances the immune response (e.g., an adjuvant added to bacterial or viral vaccines).